Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Identifieur interne : 004C00 ( Main/Merge ); précédent : 004B99; suivant : 004C01Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Auteurs : J. Yale [Canada] ; G. Bakris [États-Unis] ; B. Cariou [France] ; D. Yue [Australie] ; E. David-Neto [Brésil] ; L. Xi [États-Unis] ; K. Figueroa [États-Unis] ; E. Wajs [Belgique] ; K. Usiskin [États-Unis] ; G. Meininger [États-Unis]Source :
- Diabetes, Obesity and Metabolism [ 1462-8902 ] ; 2013-05.
Descripteurs français
English descriptors
- KwdEn :
- Adjustment period, Adverse event, Advisory panels, Ahas, Baseline, Blood pressure, Body weight, Cana, Chronic kidney disease, Core treatment period, Diabetes, Diabetes care, Diabetes mellitus, Diabetes obes metab, Discontinuation, Dos, Egfr, Endpoint, Fasting plasma glucose, Genital mycotic infections, Glucose, Glucose excretion, Glycaemic, Glycaemic control, Glycaemic rescue therapy, Glycemic control, Greater reductions, Gure, Hba1c, Hypoglycaemia, Hypoglycaemia episodes, Inhibitor, Insulin, Janssen research development, Last observation, Least squares, Lipoprotein cholesterol, Ltration rate, Median, Metabolism, Metabolism table, Metformin, Original article, Original article diabetes, Other reason, Percent change, Percent change difference, Percent changes, Placebo, Placebo group, Randomized, Randomized subjects, Renal, Renal disease, Renal function, Renal function parameters, Renal impairment, Renal threshold, Rescue therapy, Research support, Secondary endpoints, Sodium glucose, Standard deviation, Standard error, Statistical comparison, Study drug, Sulphonylurea, Sulphonylurea agent, T2dm, Time point, Transient changes, Treatment groups, Treatment period, Urine.
- Teeft :
- Adjustment period, Adverse event, Advisory panels, Ahas, Baseline, Blood pressure, Body weight, Cana, Chronic kidney disease, Core treatment period, Diabetes, Diabetes care, Diabetes mellitus, Diabetes obes metab, Discontinuation, Dos, Egfr, Endpoint, Fasting plasma glucose, Genital mycotic infections, Glucose, Glucose excretion, Glycaemic, Glycaemic control, Glycaemic rescue therapy, Glycemic control, Greater reductions, Gure, Hba1c, Hypoglycaemia, Hypoglycaemia episodes, Inhibitor, Insulin, Janssen research development, Last observation, Least squares, Lipoprotein cholesterol, Ltration rate, Median, Metabolism, Metabolism table, Metformin, Original article, Original article diabetes, Other reason, Percent change, Percent change difference, Percent changes, Placebo, Placebo group, Randomized, Randomized subjects, Renal, Renal disease, Renal function, Renal function parameters, Renal impairment, Renal threshold, Rescue therapy, Research support, Secondary endpoints, Sodium glucose, Standard deviation, Standard error, Statistical comparison, Study drug, Sulphonylurea, Sulphonylurea agent, T2dm, Time point, Transient changes, Treatment groups, Treatment period, Urine.
Abstract
Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].
Url:
- https://api.istex.fr/document/3E46F81A4B18835C6DC50A5868041B88751EAA96/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654568
DOI: 10.1111/dom.12090
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B63
- to stream Istex, to step Curation: 000B63
- to stream Istex, to step Checkpoint: 000386
- to stream Pmc, to step Corpus: 002414
- to stream Pmc, to step Curation: 002264
- to stream Pmc, to step Checkpoint: 001B58
- to stream Ncbi, to step Merge: 001159
- to stream Ncbi, to step Curation: 001159
- to stream Ncbi, to step Checkpoint: 001159
Links to Exploration step
ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title><author><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name></author><author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name></author><author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name></author><author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name></author><author><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name></author><author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name></author><author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name></author><author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/dom.12090</idno><idno type="url">https://api.istex.fr/document/3E46F81A4B18835C6DC50A5868041B88751EAA96/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B63</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B63</idno><idno type="wicri:Area/Istex/Curation">000B63</idno><idno type="wicri:Area/Istex/Checkpoint">000386</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000386</idno><idno type="wicri:doubleKey">1462-8902:2013:Yale J:efficacy:and:safety</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654568</idno><idno type="RBID">PMC:3654568</idno><idno type="wicri:Area/Pmc/Corpus">002414</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002414</idno><idno type="wicri:Area/Pmc/Curation">002264</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002264</idno><idno type="wicri:Area/Pmc/Checkpoint">001B58</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001B58</idno><idno type="wicri:Area/Ncbi/Merge">001159</idno><idno type="wicri:Area/Ncbi/Curation">001159</idno><idno type="wicri:Area/Ncbi/Checkpoint">001159</idno><idno type="wicri:doubleKey">1462-8902:2013:Yale J:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">004C00</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title><author><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Royal Victoria Hospital and McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, The University of Chicago Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Endocrinology & Center of Clinical Investigation, Nantes University Hospital, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Diabetes Centre, Royal Prince Alfred Hospital,University of Sydney, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name><affiliation wicri:level="3"><country xml:lang="fr">Brésil</country><wicri:regionArea>Núcleo Avançado de Netrologia, Hospital Sírio‐Libanês, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Biotech, Inc, PA, Spring House</wicri:regionArea><wicri:noRegion>Spring House</wicri:noRegion></affiliation></author><author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Diabetes, Obesity and Metabolism</title><title level="j" type="alt">DIABETES, OBESITY AND METABOLISM</title><idno type="ISSN">1462-8902</idno><idno type="eISSN">1463-1326</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="463">463</biblScope><biblScope unit="page" to="473">473</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-05">2013-05</date></imprint><idno type="ISSN">1462-8902</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-8902</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjustment period</term><term>Adverse event</term><term>Advisory panels</term><term>Ahas</term><term>Baseline</term><term>Blood pressure</term><term>Body weight</term><term>Cana</term><term>Chronic kidney disease</term><term>Core treatment period</term><term>Diabetes</term><term>Diabetes care</term><term>Diabetes mellitus</term><term>Diabetes obes metab</term><term>Discontinuation</term><term>Dos</term><term>Egfr</term><term>Endpoint</term><term>Fasting plasma glucose</term><term>Genital mycotic infections</term><term>Glucose</term><term>Glucose excretion</term><term>Glycaemic</term><term>Glycaemic control</term><term>Glycaemic rescue therapy</term><term>Glycemic control</term><term>Greater reductions</term><term>Gure</term><term>Hba1c</term><term>Hypoglycaemia</term><term>Hypoglycaemia episodes</term><term>Inhibitor</term><term>Insulin</term><term>Janssen research development</term><term>Last observation</term><term>Least squares</term><term>Lipoprotein cholesterol</term><term>Ltration rate</term><term>Median</term><term>Metabolism</term><term>Metabolism table</term><term>Metformin</term><term>Original article</term><term>Original article diabetes</term><term>Other reason</term><term>Percent change</term><term>Percent change difference</term><term>Percent changes</term><term>Placebo</term><term>Placebo group</term><term>Randomized</term><term>Randomized subjects</term><term>Renal</term><term>Renal disease</term><term>Renal function</term><term>Renal function parameters</term><term>Renal impairment</term><term>Renal threshold</term><term>Rescue therapy</term><term>Research support</term><term>Secondary endpoints</term><term>Sodium glucose</term><term>Standard deviation</term><term>Standard error</term><term>Statistical comparison</term><term>Study drug</term><term>Sulphonylurea</term><term>Sulphonylurea agent</term><term>T2dm</term><term>Time point</term><term>Transient changes</term><term>Treatment groups</term><term>Treatment period</term><term>Urine</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adjustment period</term><term>Adverse event</term><term>Advisory panels</term><term>Ahas</term><term>Baseline</term><term>Blood pressure</term><term>Body weight</term><term>Cana</term><term>Chronic kidney disease</term><term>Core treatment period</term><term>Diabetes</term><term>Diabetes care</term><term>Diabetes mellitus</term><term>Diabetes obes metab</term><term>Discontinuation</term><term>Dos</term><term>Egfr</term><term>Endpoint</term><term>Fasting plasma glucose</term><term>Genital mycotic infections</term><term>Glucose</term><term>Glucose excretion</term><term>Glycaemic</term><term>Glycaemic control</term><term>Glycaemic rescue therapy</term><term>Glycemic control</term><term>Greater reductions</term><term>Gure</term><term>Hba1c</term><term>Hypoglycaemia</term><term>Hypoglycaemia episodes</term><term>Inhibitor</term><term>Insulin</term><term>Janssen research development</term><term>Last observation</term><term>Least squares</term><term>Lipoprotein cholesterol</term><term>Ltration rate</term><term>Median</term><term>Metabolism</term><term>Metabolism table</term><term>Metformin</term><term>Original article</term><term>Original article diabetes</term><term>Other reason</term><term>Percent change</term><term>Percent change difference</term><term>Percent changes</term><term>Placebo</term><term>Placebo group</term><term>Randomized</term><term>Randomized subjects</term><term>Renal</term><term>Renal disease</term><term>Renal function</term><term>Renal function parameters</term><term>Renal impairment</term><term>Renal threshold</term><term>Rescue therapy</term><term>Research support</term><term>Secondary endpoints</term><term>Sodium glucose</term><term>Standard deviation</term><term>Standard error</term><term>Statistical comparison</term><term>Study drug</term><term>Sulphonylurea</term><term>Sulphonylurea agent</term><term>T2dm</term><term>Time point</term><term>Transient changes</term><term>Treatment groups</term><term>Treatment period</term><term>Urine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Diabète</term><term>Glucose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].</div></front></TEI><double doi="10.1111/dom.12090"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title><author><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name></author><author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name></author><author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name></author><author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name></author><author><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name></author><author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name></author><author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name></author><author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/dom.12090</idno><idno type="url">https://api.istex.fr/document/3E46F81A4B18835C6DC50A5868041B88751EAA96/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B63</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B63</idno><idno type="wicri:Area/Istex/Curation">000B63</idno><idno type="wicri:Area/Istex/Checkpoint">000386</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000386</idno><idno type="wicri:doubleKey">1462-8902:2013:Yale J:efficacy:and:safety</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title><author><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Royal Victoria Hospital and McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, The University of Chicago Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Endocrinology & Center of Clinical Investigation, Nantes University Hospital, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Diabetes Centre, Royal Prince Alfred Hospital,University of Sydney, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name><affiliation wicri:level="3"><country xml:lang="fr">Brésil</country><wicri:regionArea>Núcleo Avançado de Netrologia, Hospital Sírio‐Libanês, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Biotech, Inc, PA, Spring House</wicri:regionArea><wicri:noRegion>Spring House</wicri:noRegion></affiliation></author><author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Diabetes, Obesity and Metabolism</title><title level="j" type="alt">DIABETES, OBESITY AND METABOLISM</title><idno type="ISSN">1462-8902</idno><idno type="eISSN">1463-1326</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="463">463</biblScope><biblScope unit="page" to="473">473</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-05">2013-05</date></imprint><idno type="ISSN">1462-8902</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-8902</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjustment period</term><term>Adverse event</term><term>Advisory panels</term><term>Ahas</term><term>Baseline</term><term>Blood pressure</term><term>Body weight</term><term>Cana</term><term>Chronic kidney disease</term><term>Core treatment period</term><term>Diabetes</term><term>Diabetes care</term><term>Diabetes mellitus</term><term>Diabetes obes metab</term><term>Discontinuation</term><term>Dos</term><term>Egfr</term><term>Endpoint</term><term>Fasting plasma glucose</term><term>Genital mycotic infections</term><term>Glucose</term><term>Glucose excretion</term><term>Glycaemic</term><term>Glycaemic control</term><term>Glycaemic rescue therapy</term><term>Glycemic control</term><term>Greater reductions</term><term>Gure</term><term>Hba1c</term><term>Hypoglycaemia</term><term>Hypoglycaemia episodes</term><term>Inhibitor</term><term>Insulin</term><term>Janssen research development</term><term>Last observation</term><term>Least squares</term><term>Lipoprotein cholesterol</term><term>Ltration rate</term><term>Median</term><term>Metabolism</term><term>Metabolism table</term><term>Metformin</term><term>Original article</term><term>Original article diabetes</term><term>Other reason</term><term>Percent change</term><term>Percent change difference</term><term>Percent changes</term><term>Placebo</term><term>Placebo group</term><term>Randomized</term><term>Randomized subjects</term><term>Renal</term><term>Renal disease</term><term>Renal function</term><term>Renal function parameters</term><term>Renal impairment</term><term>Renal threshold</term><term>Rescue therapy</term><term>Research support</term><term>Secondary endpoints</term><term>Sodium glucose</term><term>Standard deviation</term><term>Standard error</term><term>Statistical comparison</term><term>Study drug</term><term>Sulphonylurea</term><term>Sulphonylurea agent</term><term>T2dm</term><term>Time point</term><term>Transient changes</term><term>Treatment groups</term><term>Treatment period</term><term>Urine</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adjustment period</term><term>Adverse event</term><term>Advisory panels</term><term>Ahas</term><term>Baseline</term><term>Blood pressure</term><term>Body weight</term><term>Cana</term><term>Chronic kidney disease</term><term>Core treatment period</term><term>Diabetes</term><term>Diabetes care</term><term>Diabetes mellitus</term><term>Diabetes obes metab</term><term>Discontinuation</term><term>Dos</term><term>Egfr</term><term>Endpoint</term><term>Fasting plasma glucose</term><term>Genital mycotic infections</term><term>Glucose</term><term>Glucose excretion</term><term>Glycaemic</term><term>Glycaemic control</term><term>Glycaemic rescue therapy</term><term>Glycemic control</term><term>Greater reductions</term><term>Gure</term><term>Hba1c</term><term>Hypoglycaemia</term><term>Hypoglycaemia episodes</term><term>Inhibitor</term><term>Insulin</term><term>Janssen research development</term><term>Last observation</term><term>Least squares</term><term>Lipoprotein cholesterol</term><term>Ltration rate</term><term>Median</term><term>Metabolism</term><term>Metabolism table</term><term>Metformin</term><term>Original article</term><term>Original article diabetes</term><term>Other reason</term><term>Percent change</term><term>Percent change difference</term><term>Percent changes</term><term>Placebo</term><term>Placebo group</term><term>Randomized</term><term>Randomized subjects</term><term>Renal</term><term>Renal disease</term><term>Renal function</term><term>Renal function parameters</term><term>Renal impairment</term><term>Renal threshold</term><term>Rescue therapy</term><term>Research support</term><term>Secondary endpoints</term><term>Sodium glucose</term><term>Standard deviation</term><term>Standard error</term><term>Statistical comparison</term><term>Study drug</term><term>Sulphonylurea</term><term>Sulphonylurea agent</term><term>T2dm</term><term>Time point</term><term>Transient changes</term><term>Treatment groups</term><term>Treatment period</term><term>Urine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Diabète</term><term>Glucose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].</div></front></TEI></ISTEX><PMC><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title><author><name sortKey="Yale, J F" sort="Yale, J F" uniqKey="Yale J" first="J-F" last="Yale">J-F Yale</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Medicine, Royal Victoria Hospital and McGill University</institution><addr-line>Montreal, Canada</addr-line></nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Montreal</wicri:regionArea></affiliation></author><author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G" last="Bakris">G. Bakris</name><affiliation wicri:level="2"><nlm:aff id="au2"><institution>Department of Medicine, The University of Chicago Medicine</institution><addr-line>Chicago, IL, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B" last="Cariou">B. Cariou</name><affiliation wicri:level="1"><nlm:aff id="au3"><institution>Department of Endocrinology & Center of Clinical Investigation, Nantes University Hospital</institution><addr-line>Nantes, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Nantes</wicri:regionArea></affiliation></author><author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D" last="Yue">D. Yue</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Diabetes Centre, Royal Prince Alfred Hospital,University of Sydney</institution><addr-line>Camperdown, Australia</addr-line></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="David Neto, E" sort="David Neto, E" uniqKey="David Neto E" first="E" last="David-Neto">E. David-Neto</name><affiliation wicri:level="1"><nlm:aff id="au5"><institution>Núcleo Avançado de Netrologia, Hospital Sírio-Libanês</institution><addr-line>São Paulo, Brazil</addr-line></nlm:aff><country xml:lang="fr">Brésil</country><wicri:regionArea>São Paulo</wicri:regionArea></affiliation></author><author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L" last="Xi">L. Xi</name><affiliation wicri:level="2"><nlm:aff id="au6"><institution>Janssen Biotech, Inc</institution><addr-line>Spring House, PA, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Spring House, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K" last="Figueroa">K. Figueroa</name><affiliation wicri:level="2"><nlm:aff id="au7"><institution>Janssen Research & Development, LLC</institution><addr-line>Raritan, NJ, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E" last="Wajs">E. Wajs</name><affiliation wicri:level="1"><nlm:aff id="au8"><institution>Janssen Research & Development</institution><addr-line>Beerse, Belgium</addr-line></nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Beerse</wicri:regionArea></affiliation></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K" last="Usiskin">K. Usiskin</name><affiliation wicri:level="2"><nlm:aff id="au7"><institution>Janssen Research & Development, LLC</institution><addr-line>Raritan, NJ, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G" last="Meininger">G. Meininger</name><affiliation wicri:level="2"><nlm:aff id="au7"><institution>Janssen Research & Development, LLC</institution><addr-line>Raritan, NJ, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23464594</idno><idno type="pmc">3654568</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654568</idno><idno type="RBID">PMC:3654568</idno><idno type="doi">10.1111/dom.12090</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">002414</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002414</idno><idno type="wicri:Area/Pmc/Curation">002264</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002264</idno><idno type="wicri:Area/Pmc/Checkpoint">001B58</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001B58</idno><idno type="wicri:Area/Ncbi/Merge">001159</idno><idno type="wicri:Area/Ncbi/Curation">001159</idno><idno type="wicri:Area/Ncbi/Checkpoint">001159</idno><idno type="wicri:doubleKey">1462-8902:2013:Yale J:efficacy:and:safety</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title><author><name sortKey="Yale, J F" sort="Yale, J F" uniqKey="Yale J" first="J-F" last="Yale">J-F Yale</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Medicine, Royal Victoria Hospital and McGill University</institution><addr-line>Montreal, Canada</addr-line></nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Montreal</wicri:regionArea></affiliation></author><author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G" last="Bakris">G. Bakris</name><affiliation wicri:level="2"><nlm:aff id="au2"><institution>Department of Medicine, The University of Chicago Medicine</institution><addr-line>Chicago, IL, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B" last="Cariou">B. Cariou</name><affiliation wicri:level="1"><nlm:aff id="au3"><institution>Department of Endocrinology & Center of Clinical Investigation, Nantes University Hospital</institution><addr-line>Nantes, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Nantes</wicri:regionArea></affiliation></author><author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D" last="Yue">D. Yue</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Diabetes Centre, Royal Prince Alfred Hospital,University of Sydney</institution><addr-line>Camperdown, Australia</addr-line></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="David Neto, E" sort="David Neto, E" uniqKey="David Neto E" first="E" last="David-Neto">E. David-Neto</name><affiliation wicri:level="1"><nlm:aff id="au5"><institution>Núcleo Avançado de Netrologia, Hospital Sírio-Libanês</institution><addr-line>São Paulo, Brazil</addr-line></nlm:aff><country xml:lang="fr">Brésil</country><wicri:regionArea>São Paulo</wicri:regionArea></affiliation></author><author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L" last="Xi">L. Xi</name><affiliation wicri:level="2"><nlm:aff id="au6"><institution>Janssen Biotech, Inc</institution><addr-line>Spring House, PA, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Spring House, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K" last="Figueroa">K. Figueroa</name><affiliation wicri:level="2"><nlm:aff id="au7"><institution>Janssen Research & Development, LLC</institution><addr-line>Raritan, NJ, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E" last="Wajs">E. Wajs</name><affiliation wicri:level="1"><nlm:aff id="au8"><institution>Janssen Research & Development</institution><addr-line>Beerse, Belgium</addr-line></nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Beerse</wicri:regionArea></affiliation></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K" last="Usiskin">K. Usiskin</name><affiliation wicri:level="2"><nlm:aff id="au7"><institution>Janssen Research & Development, LLC</institution><addr-line>Raritan, NJ, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G" last="Meininger">G. Meininger</name><affiliation wicri:level="2"><nlm:aff id="au7"><institution>Janssen Research & Development, LLC</institution><addr-line>Raritan, NJ, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><series><title level="j">Diabetes, Obesity & Metabolism</title><idno type="ISSN">1462-8902</idno><idno type="eISSN">1463-1326</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Aims</title><p>Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m<sup>2</sup>].</p></sec><sec><title>Methods</title><p>In this randomized, double-blind, placebo-controlled, phase 3 trial, subjects (N = 269) received canagliflozin 100 or 300 mg or placebo daily. The primary efficacy endpoint was change from baseline in HbA1c at week 26. Prespecified secondary endpoints were change in fasting plasma glucose (FPG) and proportion of subjects reaching HbA1c <7.0%. Safety was assessed based on adverse event (AE) reports; renal safety parameters (e.g. eGFR, blood urea nitrogen and albumin/creatinine ratio) were also evaluated.</p></sec><sec><title>Results</title><p>Both canagliflozin 100 and 300 mg reduced HbA1c from baseline compared with placebo at week 26 (–0.33, –0.44 and –0.03%; p < 0.05). Numerical reductions in FPG and higher proportions of subjects reaching HbA1c < 7.0% were observed with canagliflozin 100 and 300 mg versus placebo (27.3, 32.6 and 17.2%). Overall AE rates were similar for canagliflozin 100 and 300 mg and placebo (78.9, 74.2 and 74.4%). Slightly higher rates of urinary tract infections and AEs related to osmotic diuresis and reduced intravascular volume were observed with canagliflozin 300 mg compared with other groups. Transient changes in renal function parameters that trended towards baseline over 26 weeks were observed with canagliflozin.</p></sec><sec><title>Conclusion</title><p>Canagliflozin improved glycaemic control and was generally well tolerated in subjects with T2DM and Stage 3 CKD.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Kramer, H" uniqKey="Kramer H">H Kramer</name></author><author><name sortKey="Molitch, Me" uniqKey="Molitch M">ME Molitch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Flynn, C" uniqKey="Flynn C">C Flynn</name></author><author><name sortKey="Bakris, G" uniqKey="Bakris G">G Bakris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cavanaugh, Kl" uniqKey="Cavanaugh K">KL Cavanaugh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Inzucchi, Se" uniqKey="Inzucchi S">SE Inzucchi</name></author><author><name sortKey="Bergenstal, Rm" uniqKey="Bergenstal R">RM Bergenstal</name></author><author><name sortKey="Buse, Jb" uniqKey="Buse J">JB Buse</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Nomura, S" uniqKey="Nomura S">S Nomura</name></author><author><name sortKey="Sakamaki, S" uniqKey="Sakamaki S">S Sakamaki</name></author><author><name sortKey="Hongu, M" uniqKey="Hongu M">M Hongu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sha, S" uniqKey="Sha S">S Sha</name></author><author><name sortKey="Devineni, D" uniqKey="Devineni D">D Devineni</name></author><author><name sortKey="Ghosh, A" uniqKey="Ghosh A">A Ghosh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, Y" uniqKey="Liang Y">Y Liang</name></author><author><name sortKey="Arakawa, K" uniqKey="Arakawa K">K Arakawa</name></author><author><name sortKey="Ueta, K" uniqKey="Ueta K">K Ueta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Devineni, D" uniqKey="Devineni D">D Devineni</name></author><author><name sortKey="Morrow, L" uniqKey="Morrow L">L Morrow</name></author><author><name sortKey="Hompesch, M" uniqKey="Hompesch M">M Hompesch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rosenstock, J" uniqKey="Rosenstock J">J Rosenstock</name></author><author><name sortKey="Aggarwal, N" uniqKey="Aggarwal N">N Aggarwal</name></author><author><name sortKey="Polidori, D" uniqKey="Polidori D">D Polidori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Polidori, D" uniqKey="Polidori D">D Polidori</name></author><author><name sortKey="Sakai, M" uniqKey="Sakai M">M Sakai</name></author><author><name sortKey="Devineni, D" uniqKey="Devineni D">D Devineni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levey, As" uniqKey="Levey A">AS Levey</name></author><author><name sortKey="Coresh, J" uniqKey="Coresh J">J Coresh</name></author><author><name sortKey="Greene, T" uniqKey="Greene T">T Greene</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Niskanen, L" uniqKey="Niskanen L">L Niskanen</name></author><author><name sortKey="Cefalu, Wt" uniqKey="Cefalu W">WT Cefalu</name></author><author><name sortKey="Leiter, La" uniqKey="Leiter L">LA Leiter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schernthaner, G" uniqKey="Schernthaner G">G Schernthaner</name></author><author><name sortKey="Gross, J" uniqKey="Gross J">J Gross</name></author><author><name sortKey="Fu, M" uniqKey="Fu M">M Fu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stenlof, K" uniqKey="Stenlof K">K Stenlof</name></author><author><name sortKey="Cefalu, Wt" uniqKey="Cefalu W">WT Cefalu</name></author><author><name sortKey="Tong, C" uniqKey="Tong C">C Tong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilding, J" uniqKey="Wilding J">J Wilding</name></author><author><name sortKey="Mathieu, C" uniqKey="Mathieu C">C Mathieu</name></author><author><name sortKey="Deng, L" uniqKey="Deng L">L Deng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Devineni, D" uniqKey="Devineni D">D Devineni</name></author><author><name sortKey="Marbury, Tc" uniqKey="Marbury T">TC Marbury</name></author><author><name sortKey="Curtin, Cr" uniqKey="Curtin C">CR Curtin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buse, Jb" uniqKey="Buse J">JB Buse</name></author><author><name sortKey="Henry, Rr" uniqKey="Henry R">RR Henry</name></author><author><name sortKey="Han, J" uniqKey="Han J">J Han</name></author><author><name sortKey="Kim, Dd" uniqKey="Kim D">DD Kim</name></author><author><name sortKey="Fineman, Ms" uniqKey="Fineman M">MS Fineman</name></author><author><name sortKey="Baron, Ad" uniqKey="Baron A">AD Baron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hermansen, K" uniqKey="Hermansen K">K Hermansen</name></author><author><name sortKey="Kipnes, M" uniqKey="Kipnes M">M Kipnes</name></author><author><name sortKey="Luo, E" uniqKey="Luo E">E Luo</name></author><author><name sortKey="Fanurik, D" uniqKey="Fanurik D">D Fanurik</name></author><author><name sortKey="Khatami, H" uniqKey="Khatami H">H Khatami</name></author><author><name sortKey="Stein, P" uniqKey="Stein P">P Stein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kendall, Dm" uniqKey="Kendall D">DM Kendall</name></author><author><name sortKey="Riddle, Mc" uniqKey="Riddle M">MC Riddle</name></author><author><name sortKey="Rosenstock, J" uniqKey="Rosenstock J">J Rosenstock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strojek, K" uniqKey="Strojek K">K Strojek</name></author><author><name sortKey="Yoon, Kh" uniqKey="Yoon K">KH Yoon</name></author><author><name sortKey="Hruba, V" uniqKey="Hruba V">V Hruba</name></author><author><name sortKey="Elze, M" uniqKey="Elze M">M Elze</name></author><author><name sortKey="Langkilde, Am" uniqKey="Langkilde A">AM Langkilde</name></author><author><name sortKey="Parikh, S" uniqKey="Parikh S">S Parikh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilding, Jp" uniqKey="Wilding J">JP Wilding</name></author><author><name sortKey="Woo, V" uniqKey="Woo V">V Woo</name></author><author><name sortKey="Soler, Ng" uniqKey="Soler N">NG Soler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Zeeuw, D" uniqKey="De Zeeuw D">D de Zeeuw</name></author><author><name sortKey="Remuzzi, G" uniqKey="Remuzzi G">G Remuzzi</name></author><author><name sortKey="Parving, Hh" uniqKey="Parving H">HH Parving</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Kohan, De" uniqKey="Kohan D">DE Kohan</name></author><author><name sortKey="Fioretto, P" uniqKey="Fioretto P">P Fioretto</name></author><author><name sortKey="List, J" uniqKey="List J">J List</name></author><author><name sortKey="Tang, W" uniqKey="Tang W">W Tang</name></author></analytic></biblStruct></listBibl></div1></back></TEI></PMC></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C00 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004C00 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96
|texte= Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
}}
| This area was generated with Dilib version V0.6.33. |  |